Compare Citius Pharmaceuticals Inc (CTXR) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Philip Morris International Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Philip Morris International Inc. trades at $186.39 (market cap $289.90B). The key difference: Philip Morris International Inc. is far larger — about 15477.8× Citius Pharmaceuticals Inc's market cap, and Philip Morris International Inc. pays a 3.16% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | PM | |
|---|---|---|
Market Cap | $18.73M | $289.90B |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $200.17 |
52-Week Low | $0.48 | $144.33 |
Enterprise Value | $14.95M | $333.02B |
Dividend Yield | — | 3.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Philip Morris International (PM) trades at $186.22, down 1.77% with mixed technical signals. The company reported strong Q1 and Q2 2026 earnings beats but faces margin pressure from rising costs. Revenue grew to $40.65B in 2025 with a robust 25.56% net income margin. Analyst consensus remains bullish with a $211.17 price target, though recent news highlights challenges including a $500M impairment charge and increased illicit cigarette trade in Europe.
PM offers solid fundamentals with high profitability and dividend yield, but near-term headwinds from cost inflation and regulatory risks warrant caution. The stock's valuation at 25.54x P/E is reasonable given earnings growth potential, making it attractive for long-term investors despite current volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
